Drug profile · INN
fosdenopterin hydrobromide
NULIBRY
fosdenopterin hydrobromide (NULIBRY) is a unknown. Route of administration: intravenous. Current US regulatory status: approved.
FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — fosdenopterin hydrobromide
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
fosdenopterin hydrobromide (NULIBRY) is a unknown. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
INN fosdenopterin hydrobromide
Brand NULIBRY
Mechanism Unknown
Route INTRAVENOUS
Formulation POWDER
Mechanism of action
Unknown
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Frequently asked questions
What is fosdenopterin hydrobromide?
fosdenopterin hydrobromide (NULIBRY) is a unknown. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for fosdenopterin hydrobromide?
NULIBRY is a marketed brand name for fosdenopterin hydrobromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of fosdenopterin hydrobromide?
fosdenopterin hydrobromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.